A two-year partnership with Ultrahuman aims to connect clinical biomarkers and wearable data, bringing aging assessment into ...
GPX4-targeting therapy reduces epigenetic age markers and circulating inflammation, raising questions about effects beyond ...
Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well ...
MUST’s RETRO-EPIGERNA team won $1 million and a place in the $81 million finals, though key trial details remain undisclosed.
A new partnership is combining a blood test, a cognitive app and national infrastructure to cut Britain’s years-long ...
Neither the FDA nor EMA recognizes aging as an indication – but the drafts, the precedent and the people on record are ...
Oxford biotech secures $47 million to scale cell-based mRNA manufacturing, with an eye on therapies that require repeated ...
Deep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every ...
The Parkinson’s enzyme therapy is still heading toward the clinic, and the deal could grow by up to $1.17bn in milestone ...
The Austin-based microbiome testing company raised a $33M Series B, and adults now outnumber babies in its testing volume.
Swedish biotech will present the Phase II ADVANCE trial design for vaccine candidate ALZ-101 at Alzheimer’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results